Delivery Order SPE2DB24D2100-SPE2DB25FBGMS
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $29,794.79 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on September 8, 2025, with completion targeted for September 9, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen,...
- The Defense Logistics Agency awarded a delivery order valued at $25,169.28 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,144.72 by the Defense Logistics Agency on August 4, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL). This competitively awarded, firm fixed-price contract carries no set-aside designation and is scheduled for completion by August 5, 2025. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,617.14 by the Defense Logistics Agency on September 11, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $6,391.17 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on June 26, 2025, with completion scheduled for June 27, 2025. This firm fixed-price contract, which was competitively awarded with no set-aside designation, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The company, headquartered in Conshohocken, Pennsylvania, serves as a major...
- The Defense Logistics Agency awarded a delivery order valued at $18,639.99 to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 ml pen injections. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $12,374.91 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors. The contract is competitively awarded with no set-aside designation and operates under a firm fixed-price structure with a delivery completion date of May 15, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is issued under...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $61,126.46 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 31, 2025, with an ultimate completion date of August 1, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBGMSDelivery Order
The Defense Logistics Agency awarded a $26,459.82 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors, with an ultimate completion date of September 22, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military and federal healthcare systems. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies an extensive portfolio of medications and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. Dupixent, a specialty biologic medication commonly used for treating atopic dermatitis, eosinophilic esophagitis, and asthma, represents one of many pharmaceutical products distributed through this prime vendor contract. AmerisourceBergen's consistent selection through open competition and its substantial contract values demonstrate the company's established capability to meet rigorous federal procurement requirements for specialized medical commodities supporting military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.5k | 9/19/25 |